
Regeneron Pharmaceuticals, Inc.: updates and filings
Price
$923.34
November 19, 2026Market cap $96.6B
What Ploutos Investor adds for Regeneron Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 30, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
September 2026
July 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 19, 2026Shares registered for employeesFormS-8
- Nov 5, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Oct 30, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 30, 2026Results of operationsForm8-K
- Oct 6, 2026Material agreement entered, results of operations, other material eventsForm8-K
- Sep 30, 2026Officer or director changeForm8-K
- Aug 20, 2026FilingFormN-PX
- Aug 7, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operationsForm8-K
- Jul 6, 2026Results of operationsForm8-K
- Jun 17, 2026Shareholder voteForm8-K
- May 8, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 29, 2026Results of operationsForm8-K
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Additional annual meeting materialFormDEFA14A
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Apr 8, 2026Results of operationsForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 6, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Feb 4, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Jan 30, 2026Results of operationsForm8-K
- Jan 12, 2026Results of operations, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 19, 2026 | S-8 | Shares registered for employees | Document |
| Nov 5, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Oct 30, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 30, 2026 | 8-K | Results of operations | Document |
| Oct 6, 2026 | 8-K | Material agreement entered, results of operations, other material events | Document |
| Sep 30, 2026 | 8-K | Officer or director change | Document |
| Aug 20, 2026 | N-PX | Filing | Document |
| Aug 7, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations | Document |
| Jul 6, 2026 | 8-K | Results of operations | Document |
| Jun 17, 2026 | 8-K | Shareholder vote | Document |
| May 8, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 29, 2026 | 8-K | Results of operations | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 8, 2026 | 8-K | Results of operations | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 6, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Feb 4, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Jan 30, 2026 | 8-K | Results of operations | Document |
| Jan 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 26, 1995.
The full analysis
What do Regeneron Pharmaceuticals's filings show?
The filings are where every one of Regeneron Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.